Advancing Cell And Gene Therapies Through Closed Aseptic Processes

Lab Testing GettyImages-1097343012

The U.S. Food and Drug Administration (FDA) has approved 25 cell and gene therapies (C & GTs) since 2017 and predicts that, by 2025, it will license as many as 20 new treatments per year. This prediction may be an underestimate, as C & GTs become "industrialized" through the application of allogeneic cells and platform processes and through the expansion of treatable disease states.

With more than 800 cell or gene therapies at the Investigational New Drug (IND) development stage, pipelines are now at full capacity. However, sponsors still rely on outdated production methodology borrowed from therapeutic protein processes. To support this rapid growth, best-in-class contract development and manufacturing organizations (CDMOs) are investing in development and manufacturing technologies to meet the needs of rapidly-emerging development programs.

The industrialization of cell and gene therapies will require a deep appreciation of the biological roles of key components, including advanced viral vector production technologies and adoption of allogeneic cell therapies to achieve scalability.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies